

BIOGRAPHICAL SKETCH			
<b>NAME:</b> COOPER, Wendy		<b>POSITION TITLE:</b> A/Professor	
<b>EDUCATION/TRAINING:</b>			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
University of Sydney	MBBS (Hons I)	1998	Medicine
University of Sydney	B.Sc.(Med) (Hons I)	1996	
Royal College of Pathologist of Australasia	Fellowship	2004	Pathology
University of Sydney	PhD	2008	

**Personal Statement:**

A/Prof Wendy Cooper is a Staff Specialist in Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital. She has a broad range of interests in surgical pathology with special interest and expertise in pulmonary pathology, molecular oncology and haematopathology. She is a Clinical Associate Professor at the University of Sydney and Conjoint Associate Professor at the Western Sydney University. She is a Visiting Scientist at the Garvan Institute of Medical Research and a member of the Sydney Catalyst (Translational Cancer Research) T1 Working Group with her main research interests being in lung cancer.

Wendy graduated from Medicine at the University of Sydney with First Class Honours in 1998. She also received a Bachelor of Science (Med) with First Class Honours in 1996. She obtained her Fellowship from the Royal Australasian College of Pathologists in 2004 and in 2008 completed a PhD from the University of Sydney titled "Molecular makers of prognosis in early stage non-small cell lung cancer" for which she received the prestigious Peter Bancroft Prize. Her current major research interest is in prognostic and predictive biomarkers in lung cancer.

**Publications:**

- Bremnes RM, Lill-Tove Busund LT, Thomas L. Kilv er TL, Erna Elise Paulsen EE, Hald S, Rakaekhanehkenari M, Cooper WA, Kao SC, D nnem T. The role of tumor infiltrating lymphocytes in development, progression and prognosis of non-small cell lung cancer. J Thorac Oncol. 2016 Feb 1 [Epub ahead of print].
- Anderson S, Sasson SC, Lee FJ, Larsen S, Cooper W, Garsia R. Episodic fevers and vasodilatory shock mimicking urosepsis in a patient with HIV-associated Multicentric Castleman's Disease: a case report. BMC Infect Dis. 2015; 16: 53.
- Lyle M, Haydu LE, Menzies, AM, Thompson JF, Saw RPM, Spillane AJ, Kefford RJ, Mann GJ, Cooper WA, Yu B, Scolyer RA, O'Toole SA, Long GV. The molecular profile of metastatic melanoma in Australia. Pathology. 2016. 48:188-193.
- Li BT, Lee A, O'Toole S, Cooper W, Yu B, Chaft JE, Arcila ME, Kris MG, Pavlakis N. HER2 insertion YVMA mutant lung cancer: long natural history and response to afatinib. Lung Cancer 2015; 90: 617-9.

- Kao, SC, Kirschner MB, Cooper WA, Tran T, Burgers S, Wright C, Korse, T, van den Broek D, Edelman J, Vallely M, McCaughan B, Pavlakis N, Clarke S, Molloy M, van Zandwijk N, Reid G. A proteomics-based approach identifies Secreted Protein Acidic and Rich in Cysteine (SPARC) in malignant pleural mesothelioma. *Br J Cancer* 2016; 114:524-31.
- Tran, T.N., Selinger, C.I., Kohonen-Corish, M.R.J., McCaughan, B., Kennedy, C., O'Toole, S.A., Cooper, W.A. Alterations of MET gene copy number and protein expression in primary non-small cell lung cancer and nodal metastases. *Clinical Lung Cancer*. 2016; 17:30-38.
- Kao, S.C., Fulham, M., Wong, K., Cooper, W., Sagong, J.O. Boyer, M. Pattison, S., Brahmabhatt, H., MacDiarmid, J., Reid, G., van Zandwijk, N. A significant metabolic and radiological response following a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. *American Journal of Respiratory and Critical Care Medicine*. 2015; 191:1467-1469.
- Williams M, Kirschner MB, Cheng YY, Hanh J, Weiss J, Mugridge N, Wright CM, Linton A, Kao SC, Edelman JB, Vallely MP, McCaughan BC, Cooper W, Klebe S, Lin RCY, Brahmabhatt H, MacDiarmid J, van Zandwijk N, Reid G. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. *Oncotarget*. 2015; 6:23480-95.
- Selinger, C., Cooper, W., Lum, T., McNeil, C., Morey, A., Waring, P., Amanuel, B., Millward, M., Peverall, J., Van Vliet, C., Christie, M., Tran, Y., Diakos, C., Pavlakis, N., Gill, A.J., O'Toole, S.A. Equivocal ALK FISH cases may benefit from ancillary ALK FISH probe testing. *Histopathology* 201;67:654-63.
- Cooper, W.A., Tran, T., Madore, J., Selinger, C., Kohonen-Corish, M., Yip, P.Y., O'Toole, S.A., McCaughan, B.C., Horvath, L., Kao, S., Boyer, M., Scolyer, R.A. PD-L1 expression is a favourable prognostic factor in early stage NSCLC. *Lung Cancer*. 2015; 89:181-188.
- Wang, S., Yu, B., Ng, C.C., Mercorella, B., Selinger, C.I., O'Toole, S.A., Cooper, W.A. The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. *Translational Lung Cancer Research*. 2015; 4:119-125.
- Luk, P.P., Yu, B., Ng, C.C., Mercorella, B., Selinger, C., Lum, T., Kao, S., O'Toole, S.A., Cooper, W.A. BRAF mutations in non-small cell lung cancer. *Translational Lung Cancer Research*. 2015; 4:142-148.